2023 Meeting Magazine - 9

Now Approved: IV FORMULATION
COSENTYX® (secukinumab)
Joint Decision-Making
Novartis Pharmaceuticals Corporation invites you to join this immersive program as
you assume the role of the healthcare professional and guide simulated interactions
with 2 hypothetical patients, Mark and Melanie. Their symptoms tell a story.
Listen to these hypothetical patients. Engage in discussion.
Help guide their treatment journey.
Program Details
Presented by: Linda Grinnell Merrick, MS, NP-C & Vishal Medatia
Monday, November 13, 2023
11:30 am - 12:15 pm PT Program
Exhibit Halls GH Innovation Theater B * San Diego Convention Center * San Diego, California
Meal will be provided.
To learn more about COSENTYX, visit booth 1401.
Sponsored by Novartis Pharmaceuticals Corporation
Novartis Pharmaceuticals Corporation (NPC) may not be able to offer you food or beverages if you are licensed by a state with a meal limit or prohibition,
if you are a government employee or member of a formulary committee, or if your institution or affiliation prohibits your acceptance of a meal from a
pharmaceutical industry representative. NPC relies on you to ensure mutual compliance with all applicable laws and policies.
Novartis acts in accordance with the PhRMA Code on Interactions With Health Care Professionals. The PhRMA Code states that inclusion of a health care
professional's spouse or guest at an educational program is not appropriate. Your support of these ethical guidelines will help to ensure a high quality
learning environment for all participating health care professionals. Thank you.
This program does not qualify for continuing medical education (CME) credit.
This program is developed and offered by Novartis Pharmaceuticals Corporation. This is not an official program of the American College of
Rheumatology Convergence 2023.
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080
© 2023 Novartis
9/23
290518

2023 Meeting Magazine

Table of Contents for the Digital Edition of 2023 Meeting Magazine